The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients

详细信息    查看全文

• 作者：Zhenqian Wu¹ ; Xiuyan Huang¹ ; Xiaodong Han ; Zhongnan Li ; Qinchao Zhu ; Jun Yan ; Song Yu ; Zhiming Jin ; Zhigang Wang ; Qi Zheng ; Yu Wang ; ^{wangyu11122@sina.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：CXCL9 ; Chemokine ; Colorectal carcinoma ; Prognosis
• 刊名：Biomedicine & Pharmacotherapy
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：78
• 期：Complete
• 页码：8-13
• 全文大小：1267 K

文摘

The chemokine CXCL9 has been demonstrated to play an important role in the development of human malignancies. However, its prognostic significance in cancer patients remains unclear and less is known about its role in colonrectal carcinoma (CRC) patients. In this study, we found that the relative mRNA expression level of CXCL9 in primary colorectal tumor tissues was significantly higher than that in corresponding normal colon tissues. CXCL9 protein expression was also detected in 102 of 130 primary CRC patients by immunochemistry. Thus, CXCL9 might play a vital role in the progression of colorectal cancer. By analyzing the correlation between clinicopathological factors of patients and expression of CXCL9 protein, we showed that the expression of CXCL9 was significantly associated with tumor differentiation, tumor invasion, lymph node metastasis, distant metastasis, and vascular invasion, but not with other factors of CRC patients including age, gender, tumor location and tumor size. Furthermore, by performing Kaplan–Meier method as well as Cox’s univariate and multivariate hazard regression model, we found that the higher the CXCL9 expression, the higher overall survival rate was observed, and CXCL9 expression was a significant independent prognostic factor for CRC patients. Therefore, CXCL9 is a useful predictor of better clinical outcome in CRC patients.